Treatment-free remission after stopping second-line dasatinib.

    Research output: Contribution to journalComment/debate


    Treatment-free remission after treatment with a tyrosine-kinase inhibitor (TKI) for chronic myeloid leukaemia is gaining increasing importance, as it offers patients freedom from treatment-related toxic effects and reduces long-term treatment costs. Several studies of imatinib discontinuation have been reported, but the Japanese Dasatinib Discontinuation (DADI) trial reported by Jun Imagawa and colleagues in The Lancet Haematology prospectively assessed discontinuation of second-line or subsequent dasatinib.1 63 patients with chronic myeloid leukaemia who had achieved and maintained molecular response 4·0 (BCR-ABL1 0·01% or less standardised to the International Scale [IS]) for at least 1 year while taking dasatinib were enrolled. The estimated proportion of patients with treatment-free remission 6 months after treatment cessation, the primary endpoint, was 49% (95% CI 36–61). High counts of natural-killer (NK) cells and low counts of γδ+ and CD4+ regulatory T cells (CD25+ CD127low) before discontinuation were significantly correlated with treatment-free remission.
    Original languageEnglish
    Pages (from-to)e506-e507
    Number of pages2
    JournalThe Lancet Haematology
    Issue number12
    Publication statusPublished - Dec 2015


    • dasatinib
    • Treatment-free remission
    • Correspondence


    Dive into the research topics of 'Treatment-free remission after stopping second-line dasatinib.'. Together they form a unique fingerprint.

    Cite this